256 related articles for article (PubMed ID: 18165846)
1. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs).
Viola KL; Velasco PT; Klein WL
J Nutr Health Aging; 2008 Jan; 12(1):51S-7S. PubMed ID: 18165846
[TBL] [Abstract][Full Text] [Related]
2. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.
Lacor PN; Buniel MC; Furlow PW; Clemente AS; Velasco PT; Wood M; Viola KL; Klein WL
J Neurosci; 2007 Jan; 27(4):796-807. PubMed ID: 17251419
[TBL] [Abstract][Full Text] [Related]
3. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease.
Shi XD; Sun K; Hu R; Liu XY; Hu QM; Sun XY; Yao B; Sun N; Hao JR; Wei P; Han Y; Gao C
J Neurosci; 2016 Nov; 36(47):11959-11973. PubMed ID: 27881781
[TBL] [Abstract][Full Text] [Related]
4. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.
De Felice FG; Vieira MN; Bomfim TR; Decker H; Velasco PT; Lambert MP; Viola KL; Zhao WQ; Ferreira ST; Klein WL
Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1971-6. PubMed ID: 19188609
[TBL] [Abstract][Full Text] [Related]
5. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease.
Klein WL
Alzheimers Dement; 2006 Jan; 2(1):43-55. PubMed ID: 19595855
[TBL] [Abstract][Full Text] [Related]
6. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
Lambert MP; Velasco PT; Viola KL; Klein WL
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
[TBL] [Abstract][Full Text] [Related]
7. Drebrin in Alzheimer's Disease.
Ishizuka Y; Hanamura K
Adv Exp Med Biol; 2017; 1006():203-223. PubMed ID: 28865022
[TBL] [Abstract][Full Text] [Related]
8. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
Viola KL; Klein WL
Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.
Gong Y; Chang L; Viola KL; Lacor PN; Lambert MP; Finch CE; Krafft GA; Klein WL
Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10417-22. PubMed ID: 12925731
[TBL] [Abstract][Full Text] [Related]
10. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.
Catalano SM; Dodson EC; Henze DA; Joyce JG; Krafft GA; Kinney GG
Curr Top Med Chem; 2006; 6(6):597-608. PubMed ID: 16712494
[TBL] [Abstract][Full Text] [Related]
11. Synaptic changes in Alzheimer's disease and its models.
Pozueta J; Lefort R; Shelanski ML
Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
[TBL] [Abstract][Full Text] [Related]
12. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?
Klein WL
J Alzheimers Dis; 2013; 33 Suppl 1():S49-65. PubMed ID: 22785404
[TBL] [Abstract][Full Text] [Related]
13. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.
Gandy S; Simon AJ; Steele JW; Lublin AL; Lah JJ; Walker LC; Levey AI; Krafft GA; Levy E; Checler F; Glabe C; Bilker WB; Abel T; Schmeidler J; Ehrlich ME
Ann Neurol; 2010 Aug; 68(2):220-30. PubMed ID: 20641005
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.
Pitt J; Roth W; Lacor P; Smith AB; Blankenship M; Velasco P; De Felice F; Breslin P; Klein WL
Toxicol Appl Pharmacol; 2009 Oct; 240(2):189-97. PubMed ID: 19631677
[TBL] [Abstract][Full Text] [Related]
15. Synaptic targeting by Alzheimer's-related amyloid beta oligomers.
Lacor PN; Buniel MC; Chang L; Fernandez SJ; Gong Y; Viola KL; Lambert MP; Velasco PT; Bigio EH; Finch CE; Krafft GA; Klein WL
J Neurosci; 2004 Nov; 24(45):10191-200. PubMed ID: 15537891
[TBL] [Abstract][Full Text] [Related]
16. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.
Gouras GK; Tampellini D; Takahashi RH; Capetillo-Zarate E
Acta Neuropathol; 2010 May; 119(5):523-41. PubMed ID: 20354705
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.
De Felice FG; Wu D; Lambert MP; Fernandez SJ; Velasco PT; Lacor PN; Bigio EH; Jerecic J; Acton PJ; Shughrue PJ; Chen-Dodson E; Kinney GG; Klein WL
Neurobiol Aging; 2008 Sep; 29(9):1334-47. PubMed ID: 17403556
[TBL] [Abstract][Full Text] [Related]
18. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.
De Felice FG; Velasco PT; Lambert MP; Viola K; Fernandez SJ; Ferreira ST; Klein WL
J Biol Chem; 2007 Apr; 282(15):11590-601. PubMed ID: 17308309
[TBL] [Abstract][Full Text] [Related]
19. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets.
Klein WL
Neurochem Int; 2002 Nov; 41(5):345-52. PubMed ID: 12176077
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates.
Forny-Germano L; Lyra e Silva NM; Batista AF; Brito-Moreira J; Gralle M; Boehnke SE; Coe BC; Lablans A; Marques SA; Martinez AM; Klein WL; Houzel JC; Ferreira ST; Munoz DP; De Felice FG
J Neurosci; 2014 Oct; 34(41):13629-43. PubMed ID: 25297091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
